Aim: To evaluate the intraocular stability and safety of secondary iris-claw intraocular lenses (IOLs) in aphakic patients.
Methods: Eighteen eyes of 16 patients received iris-claw IOLs to correct for aphakia. Primary outcome measurements included visual acuity (6 m Snellen charts), central endothelium cell count (ECC) and intraocular position of the IOL assessed with anterior segment optical coherence tomography (OCT).
Results: Sixteen patients (mean age 66 (range 16–84) years; axial length 24.44 mm) were re-examined 22 months postoperatively (range 12–38 months). Preoperative decimal best corrected visual acuity (BCVA) was 0.51, intraocular pressure (IOP) 15.3 mmHg and central ECC 1816 per mm2. Postoperative BCVA was 0.68, IOP 13.1 mmHg and central ECC 1626 per mm2 (difference over time 176 per mm2 = 10.5%, p>0.05). The anterior chamber depth was 4 mm for the eyes with axial length <24 mm, and 4.34 mm for those ⩾24 mm.
Conclusion: Secondary anterior iris-claw IOLs appears to be a safe choice to correct aphakia with no significant intermediate postoperative central endothelium cell loss, especially in eyes with axial length ⩾24 mm, as distances from the IOL to the central and peripheral cornea proved to be consistent.
Statistics from Altmetric.com
Competing interests None declared. None of the authors have a financial or proprietary interest in any of the intraocular lenses, instrumentation or devices used in this study.
Provenance and Peer review Not commissioned; externally peer reviewed.
See Editorial, p 1273
Patient consent Obtained.